News about Amgen

This comparison of Amgen (AMGN) and Bristol Myers Squibb (BMY) uses FY 2025 financials. Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion (net margin around 21%) and free cash flow near $8.1 billion; BMY posted revenue of about $48.2 billion, nearly flat, net income of about $7.1 billion (net margin about 14.6%) and free cash flow of about $12.8 billion. The article notes Amgen faces drug pricing pressure, an ongoing IRS tax dispute and biosimilar competition, while BMY depends heavily on Eliquis and faces generic competition and government pricing constraints. It concludes BMY trades at a significantly lower valuation than Amgen, though much of its expected difficulty may already be priced in.

The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.